Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab in Infants With Severe Hemophilia A Without Inhibitors (HAVEN 7)
NCT04431726Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2021
- Primary completion
- May 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by Roche. Started Feb 2021; status: active, not recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04431726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431726.